Background: Optical spectroscopy has been studied for biologic plausibility, technical efficacy, clinical effectiveness, patient satisfaction, and cost-effectiveness.
INTRODUCTION
Advances in optical technologies for the detection of cervical cancers and precancers have shown lifesaving potential. In vivo optical spectroscopy, including fluorescence and reflectance spectroscopy, has been subjected to formal technology assessment such as biologic plausibility, technical efficacy, clinical effectiveness, patient satisfaction, and cost-effectiveness. Nearly all these reports show better performance compared with whitelight scoping in experienced hands.
Despite its superiority, the dissemination of optical spectroscopy into mainstream practice is hardly a given. Many effective technologies take years to diffuse: a meta-analysis by Balas 52 demonstrated that just 14% of all technical innovations will be incorporated into routine medical practice and this small proportion will need an average of 17 years to diffuse. Because passive diffusion is inefficient, the National Cancer Institute recommended that dissemination research be incorporated into the development of new technology. 53, 54 Theoretical models are particularly useful guides for this challenging task. Rogers' Model of Diffusion is one of the earliest and most frequently cited models of dissemination 55 (Figure 1) . Rogers lists 5 characteristics that increase an innovation's likelihood of successful dissemination: (1) if the innovation is relatively better than existing technologies; (2) if the innovation is simple to adapt; that is, its complexity; (3) the ease of trying the innovation and discarding it if it does not work; that is, its triability; (4) its compatibility with the poten-tial adopters' existing needs, values, and past experiences; and (5) the observability of the innovation's positive results.
In light of its potential to greatly improve the detection of cervical cancer, we collaborated with an industrial group to study the potential dissemination of optical spectroscopy devices in clinical practice, focusing particularly on the technology's compatibility, triability, and complexity from the vantage point of physicians who routinely screen for and diagnose cervical cancer. A total of 55 physicians were interviewed to identify the benefits of spectroscopy-based technologies and the barriers and critical issues relevant to their adoption in their own clinical practices.
MATERIALS AND METHODS Study Design
We used a 3-phase study design. In the first phase, we developed a semistructured questionnaire guide with our internal experts and later refined the guide with the scientific advisory board of a private company, Remicalm, Inc., formed to patent and license optical spectroscopy for the use of cervical cancer detection. Once the semistructured questionnaire guide was tested and refined, a series of individual interviews were conducted with 10 representative family practitioners and obstetrician gynecologists (phase 2). Finally, we conducted 3 focus groups across the United States with obstetrician gynecologists, family practitioners, and internists (phase 3) (Figure 2 ).
Phase 1 Questionnaire Development
As part of an academic-industrial collaboration, a group of academic scientists involved in technology assessment were interviewed and suggested potential barriers to the dissemination of cervical spectroscopy. Separate sessions were held with 2 gynecologic oncologists and 2 gynecologists to further suggest barriers. Feedback from these sessions was used as a basis for a semistructured questionnaire and interviewing guide for scientists at both Remicalm and at Frost and Sullivan, a testing and marketing company contracted by Remicalm to gather information on all aspects of the optical spectroscopy device's potential for adoption into Gender Medicine mainstream practice. The objective was not to obtain statistically sufficient information for analysis, but rather to characterize the range of opinions and to understand various blocking points that could affect the subsequent focus groups (a Supplemental Appendix listing the phase 1 questionnaire can be found in the online version at doi:10.1016/j.genm.2011.11.004).
Phase 2 Discussion Guide
Frost and Sullivan further developed materials for focus group sessions and elicited feedback from academic scientists at M.D. Anderson Cancer Center. The teams at M.D. Anderson, Remicalm, and Frost and Sullivan agreed on a final version of the discussion guide before the second and third phases of this study. The discussion guide asked participants about current practices in cervical cancer diagnosis, factors in their evaluation of new tech-nologies, and the pros and cons of adopting optical spectroscopy (a Supplemental Appendix listing the discussion guide can be found in the online version at doi: doi:10.1016/j.genm.2011.11.004).
Phase 2 Recruitment
We used Dr. 411, a directory of professional organization membership databases with contact information for various physician groups, to obtain a weighted convenience sample of 10 obstetric gynecologists and family practitioners from a national sample of 500. Because we wanted a sample that was 80% obstetric gynecologists and 20% family practitioners, we weighted the random sampling strategy to obtain 4 obstetrician gynecologists for every 1 family practitioner.
Phase 2 Interview Procedure
Interviews were conducted with individual physicians by interviewers employed by Frost and Sullivan (8 gynecologists and 2 family practitioners). Each individual interview lasted 60 minutes. Aspects of each physician's practice, such as number of Papanicolaou (Pap) smear tests and colposcopic examinations performed each month, were verified. Each physician was shown a presentation about the guidelines for the current management of screening and detecting cervical cancer. Physicians were then shown a presentation of the potential clinical effectiveness of optical spectroscopy for the screening and detection of cervical cancer and were asked a standardized set of interview questions regarding current practices with Pap smear, human papillomavirus (HPV) testing, colposcopy, biopsy, ThinPrep cytology, attitudes toward new technologies, importance of real-time results, and factors affecting adoption of optical spectroscopy into their clinical practice (eg, reimbursement from insurance companies, cost, and training needs).
Phase 3 Recruitment
Focus groups with primary care physicians and obstetrician gynecologists were recruited in 3 different cities in the United States. Focus groups were done in Bethesda, Maryland; Rosemont, Illinois; and Santa Clara, California. 
Phase 3 Focus Group Procedures
Focus groups were conducted at national meetings of family practitioners, obstetrician gynecologists, and primary care internists. The discussion guidelines had the following objectives: (1) characterize physician adherence to cervical cancer screening guidelines; (2) study the influence of real-time cervical diagnoses from 3 perspectives (ie, patient, physician, and payor); (3) establish interest in real-time diagnosis; (4) establish interest in optical technologies making cervical diagnosis; (5) present spectroscopy and spectroscopic approaches (ie, point probe spectroscopy that touches the tissue, large field of view spectroscopy that sees the whole cervix at 3-fold magnification, and their combination); (6) explore adoption of optical spectroscopy; (7) discuss acquisition scenarios; and (8) characterize the overall reception to such devices.
RESULTS

Phase 1 Sample and Factors identified as Salient Issues in the Dissemination of Optical Spectroscopy
The sample questions generated by study group included questions of length of practice, familiarity with cervical screening and diagnostic guidelines, number of female patients seen annually, the age range of patients seen, the number of Pap smears obtained annually, the number of colposcopies performed annually, if the physician treated cervical lesions or referred them for treatment, and if treatment was conducted what treatments were conducted and how many annually.
Phase 2 Sample
The recruitment of the 10 physicians, randomly sampled from 500, yielded 8 gynecologists and 2 family practitioners. These physicians had been in practice 14 to 31 years and were recruited so that equal numbers of those in solo, single specialty, and multiple-specialty practice settings were represented. As seen in Figure 3 , most of the sample physicians practiced near the site in which they trained. Figure 3 also shows the geographic diversity of the sample.
Phase 2 Reaction to Current Screening Guidelines
The 10 physicians followed the guidelines currently approved by both the American College of Obstetricians and Gynecologists and American Academy of Family Physicians. All 8 obstetrician gynecologists performed colposcopy and cervical treatments, but the 2 family practitioners preferred to refer their patients to gynecologists for colposcopy. All 10 physicians routinely obtained liquid cytologies for Pap smears. Seven of 10 physicians reported that they performed routine HPV testing only in women Ͻ30 years old. All performed HPV testing when cytologic abnormalities were present, per guidelines. When asked about barriers to the implementation of current accepted technologies all 10 agreed that: (1) liquid cytology was deemed expensive, (2) HPV testing was expensive, (3) the waiting period for both cytology and HPV testing was too long, and (4) colposcopy was nonspecific and led to many unnecessary biopsies and/or procedures. All physicians agreed strongly that the time and cost involved in the evaluation made patients anxious. Both family practitioners commented that they would be more likely to adopt spectroscopy if it was first adopted by gynecologists. There was disagreement on what should be the gold standard for cervical cancer diagnosis: a Pap smear test result, an HPV test, or colposcopy. None in the group insisted upon colposcopically directed biopsies as a gold standard. The doctors 
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S70 seem confused about current evidence-based screening guidelines and these results point to the evolving status of the HPV test in terms of diagnosing.
Phase 2 Reaction to Changes in Medical Practice
All 10 physicians agreed that guidelines from the American College of Obstetricians and Gynecologists and American Academy of Family Physicians were the most influential source of change in their practice of medicine, compared with: (1) reading peer-reviewed journal articles, (2) hearing about the product from patients, (3) hearing about the product from industry representatives, (4) hearing conference presentations, and (5) learning about the product from fellow physicians. They were less likely to trust product reviews in trade magazines and hearing about a product from patients, but were willing to think about results from sales representatives at conferences and hearing discussions and presentations by colleagues at conferences. Real-time diagnosis was appealing to the group because it would accelerate evaluation, decrease patient anxiety, decrease costly and unnecessary biopsies, and decrease follow-up visits.
Phase 2 Reaction to Optical Spectroscopy for Cervical Diagnosis
Each physician was shown a brief presentation about optical spectroscopy using 3 separate devices: (1) a probe that touches the cervix, (2) an imaging device that takes images of the entire cervix at 3-fold magnification, and (3) a combined device using both approaches. Physicians commented that these devices could be useful adjuncts to colposcopy and they could envision real-time diagnosis being helpful when colposcopy was indeterminent. All believed it was critically important for liability that documentation be provided and included in the medical record. Key purchasing factors included insurance reimbursement, the device paying for itself within a year, and consensus among their partners before purchase. Key adoption factors included device ease in implementation, a site visit by company representatives, and a clear reimbursement strategy.
Phase 3 Focus Groups' Recruitment Results
The larger focus groups were carried out in April 2007 in Santa Clara, California; Bethesda, Maryland; and Chicago, Illinois. Table I describes the location and composition of the focus groups. The sample's number of years of practice were assessed in quintiles of 5 years from 0 to 5 years to 41 to 45 years in practice. There were 25 primary care physicians combining family practitioners and internists, and 20 obstetrician gynecologists. The mean number of years in practice for the gynecologists was 16 to 20 years, whereas the median was 20 to 25 years. The primary care physicians' mean years of practice was 16 to 20 years, whereas the median was 11 to 15 years. The obstetrician gynecologists performed 11 to 90 Pap smear procedures per week (meanϭ50, median ϭ 50), whereas the primary care physicians performed Ͻ10 to 30 Pap smears (mean ϭ 10, medianϭ 10). All of the obstetrician gynecologists reported performing colposcopy, whereas only 1 primary care physician performed colposcopy. The obstetrician gynecologists performed Ͻ2 to 10 colposcopies per week (median ϭ 3).
Phase 3 Focus Groups' Reaction to Current Screening Guidelines
When asked about practice guidelines, most followed the American College of Obstetricians and Gynecologists and American Academy of Family Physicians and were familiar with the American So- 
Phase 3 Focus Groups' Reaction to Changes in Medical Practice
During the discussion, the physicians agreed that key opinion leaders would be an important source for information about changing their practice of medicine in this group, especially regarding the role for optical spectroscopy in the screening and diagnostic paradigm. Questions were raised as to whether or not spectroscopy had the potential to replace cytology, or the HPV test, and/or colposcopy. Other questions raised were: How would one deal with the endocervical canal? How would one prepare to use the device, discuss the results, and possibly treat the patient, all in 1 session, in a time-efficient manner?
When asked to brainstorm the attributes of the perfect screening and diagnostic device, the physicians prioritized device accuracy at the top of the list, defined as a metric using both sensitivity and specificity. However, when asked about trade-offs between sensitivity and specificity, it was noted that participants' level of understanding was insufficient as to be of great value in the analysis.
Also important was patient and provider safety and patient comfort. Others commented that the whole exam should not take more than 10 minutes, and that the ideal length of physician training range from 4 to 8 hours. In general, participants tended to spend a large proportion of time discussing issues of reimbursement, liability, and other economic issues related to their practice.
Phase 3 Focus Groups' Reaction to Optical Spectroscopy for Cervical Diagnosis
There was consistent agreement that the patients would prefer real-time diagnosis, and it was noted that one could discuss findings with the patient at that same visit rather than over the telephone. All acknowledged that patients were nonadherent to follow-up colposcopy visits, largely due to inconvenience, forgetting, lack of communication about the importance of follow-up by the provider, lack of understanding of the disease process, psychological distress leading to denial, and fear of the diagnosis and treatment.
Spectroscopy was seen as very advantageous for patients, especially for busy patients who desire to be screened and treated at the same visit. Delivery of a result was also seen as improving the quality of care. Gynecologist and primary care providers were in agreement about the patient advantages and reduction in health care costs. Both groups believed that if the device had higher sensitivity than current screening devices, then patients would be even more enthusiastic. Accuracy was considered very important to adoption by all physicians sampled. The largest barrier the physicians saw to the adoption of spectroscopy was how the device would affect work flow; many were concerned that a visit with real-time results would take Ͼ30 minutes, if treatment were included, and thus scheduling could be problematic. Because most returning patients were scheduled in 30-minute increments, device visits would potentially need 45-to 60-minute appointments (if a positive screen test was obtained). Unlike the gynecologists, many of the primary care providers believed that if they used spectroscopy instead of the Pap smear test, patients would want a second opinion. This would require a referral to a gynecologist, and thus would not save a visit. A third barrier was that physicians tended to doubt that spectroscopy would replace HPV testing. Fourth, physicians consistently expressed concern that spectroscopy not be an additional cost to the patient but rather one that received reimbursement by third-party payors. Finally, several physicians expressed concern about the device's inability to sample the endocervical canal.
All physicians acknowledged that spectroscopy could save health care costs and in principal should be considered advantageous to payors. There was universal agreement that spectroscopy could be cost-saving, but there was there was mild disagreement about payor acceptance. Some believed payors discouraged in-office procedures, some believed insurers did not support preventive care, and others worried about the entire gamut of reimbursement aspects of use. For example, if spectroscopy were used for screening it was important to the participants that the visit would be reimbursed at the cost of the office visit plus the cost of the Pap test or its rough equivalent, rather than reimbursement for the office visit alone. Others expressed fear that relationships between payors and central laboratories might discourage reimbursement. All physicians believed that if the spectroscopy device had higher sensitivity than the liquid cytology Pap test and HPV screening, then it would probably receive reimbursement. On a related note, some physicians expressed concern that they would be liable for those patients who had results that were falsely negative or falsely positive. However when asked about the high rate of loss to follow-up after colposcopy and if this was a source of liability, the physicians tended to acknowledge this to be true and agreed that the device would decrease current losses to follow-up.
DISCUSSION
Physician acceptance is critical important factor in the speed of technology dissemination. The average time for new technologies to be disseminated is Ն17 years. 53 In this study, the physicians were most concerned about the accuracy of the device, the potential for reimbursement from insurance companies, and the overall cost of the device itself.
Accuracy
Despite their intense interest in accuracy, participants did not display a detailed understanding of the tradeoffs in sensitivity and specificity, the meaning of receiver-operating characteristic curves, nor quantitatively meaningful improvements in sensitivity and specificity.
The Food and Drug Administration states that the accuracy standards for new screening technologies depend on if they will be used as (1) adjunct to colposcopy, (2) replacement for colposcopy, (3) adjunct for triage of atypical squamous cells of undetermined significance, or (4) replacement of the Pap smear for screening. To replace screening, spectroscopy must be better than both the liquid cytology Pap and the HPV test. To replace colposcopy, spectroscopy must be as good as or better than colposcopy in well-trained hands. Existing studies have examined spectroscopy as either adjuncts or replacements for colposcopy. One study 56 has evaluated spectroscopy to have a sensitivity of 50% and specificity of 90% (and performed no better than colposcopy alone), and another, 57 using a different preliminary classification algorithm, shows that spectroscopy has a sensitivity of 95% and specificity of 55%. Participants in this study may have been more familiar with data using the technology as adjunct to colposcopy. With the numbers in the literature so strikingly different, it would be difficult to assume that participants would have already had a positive view of spectroscopy. Had we asked about their previous exposure to the literature and to Food and Drug Administration indications, the focus groups might have produced more specific recommendations about the desired levels of accuracy before implementation into their own practices.
Overall, the sensitivity of the Pap (liquid or regular) smear test has been estimated at 53% to 78% and its specificity at 90% to 96%. These studies found the sensitivity of HPV testing was 96% to 100%, whereas the specificity was approximately 90%. 58, 59 Colposcopy consistently shows very high sensitivity so few cancers are missed. However, specificity is low, 50%, resulting in many patients without disease needlessly referred for additional testing and/or treatment. If spectroscopy's accuracy must be higher than Pap, HPV testing, and colposcopy to be integrated into standard care, its sensitivity should be at least 90% to 95% and its specificity at least 90%. Thus far, no research groups have achieved that level of accuracy with spectroscopic devices. However, studies of research spectroscopic devices suggest that optical spectroscopy has test characteristics comparable to liquid cytology Pap, the HPV test, and/or colposcopy, depending on the selected classification algorithm. 56 Studies are yet to be done using commercial scopes.
None of the existing studies have studied a combined approach of multispectral imaging of the entire cervix plus measurement with the point probe. The combination of the 2 approaches, will we hope allow maximization of sensitivity and specificity. A reasonable gold standard for studies of new technologies is colposcopically directed biopsies of abnormal and normal areas. One should consider endocervical curettage in everyone to rule out any involvement of the canal.
Perceived Advantages and Disadvantages Regarding Reimbursement and Costs
Study participants were quick to grasp the concept that real-time diagnosis would greatly reduce anxiety in patients; allow treatment at 1 visit; decrease the liability that comes from missed appointments; and in general, reduce the costs associated with unnecessary biopsies and treatments. They also saw some barriers. The barriers described in these surveys were:
(1) the effect on scheduling, (2) concerns about malpractice, (3) the inability of the current device to sample the endocervical canal, (4) uncertainty about third-party payors' willingness to reimburse, and (5) device cost. Other advantages mentioned included: (1) patient satisfaction through decreased anxiety waiting for results, (2) the potential to eliminate unnecessary biopsies and loop excisions, and (3) possible earlier detection of lesions.
Limitations and Strengths
There were 3 principal weaknesses of this study: (1) the sample size was small, (2) the use of spectroscopy for screening versus diagnosis was not delineated clearly during the discussions, and (3) understanding of the participants' sensitivity and specificity was not detailed.
The principal strength of this study is the indepth approach applied to the interviews, the geographic diversity, and the multispecialty approach. The manner in which the study was conducted allowed for a great deal of spontaneity, creativity, and detailed discussion.
CONCLUSIONS
This qualitative study of physician attitudes represents an initial step toward dissemination of optical spectroscopy into routine care. A larger study, including more diversity of providers, is planned. Future studies should also address payor satisfaction, which is beyond the scope of this work. Another area that should be explored in more depth is physicians' working understanding of screening paradigms and the inherent tradeoff between optimal sensitivity and specificity in balancing limited health care resources. 
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SUPPLEMENTAL MATERIAL
Supplemental material accompanying this article can be found in the online version at doi:10.1016/ j.genm.2011.11.004. Fluorescence imaging is used to determine whether a tissue is normal, pre-cancerous or cancerous. The Remiscope, the main instrument, can be thought of as a colposcope with added functionality. Illumination containing a particular blend of colors is used to obtain fluorescent images with the highest contrast between normal and abnormal tissues. The diagnosis is done by looking at a white light image, a blue light image and three colored fluorescence images. We can add a camera to record images. A fiber optic probe that directly contacts the tissue allow the doctor to get much higher sensitivity and specificity than for the entire image. With the probe, instead of receiving two or three wavelengths, we are getting a few hundred. A single number indicates whether the tissue is healthy or diseased. So in the exam, first the entire cervix is visualized. The probe is used to look at suspicious areas.
CONFLICTS OF INTEREST
The process for a repeat exam following an initial Pap smear can be shortcut. False negatives can be eliminated and a more detailed exam with the probe can be conducted in real time. And the delay in waiting for a pathology report is avoided. The gynecologist conducting the exam can take a biopsy.
Gender Medicine
S77.e5
